Literature DB >> 24902550

Trends in childhood drug-resistant tuberculosis in South Africa: a window into the wider epidemic?

H S Schaaf1, A C Hesseling1, C Rautenbach2, J A Seddon1.   

Abstract

Childhood tuberculosis (TB) is a marker of TB transmission within a community. We present the fourth consecutive survey of children with culture-confirmed TB at a hospital in Cape Town, South Africa, from 2009 to 2011. In comparison to the previous survey, the rate of multidrug-resistant TB (MDR-TB) has stabilised and the human immunodeficiency virus infection rate has declined. We also report on the first systematic surveillance of resistance to second-line drugs. Two concerns following from this are the high rate (22%) of ofloxacin resistance in MDR-TB isolates, and the discordance between isolates with an inhA promoter region mutation, usually implying ethionamide (ETH) resistance, and phenotypic ETH results in these isolates showing ETH susceptibility.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24902550     DOI： 10.5588/ijtld.13.0069

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN： 1027-3719            Impact factor:   2.373


  7 in total

1.  Epidemiology of drug-resistant tuberculosis among children and adolescents in South Africa, 2005-2010.

Authors:  B K Moore; E Anyalechi; M van der Walt; S Smith; L Erasmus; J Lancaster; S Morris; N Ndjeka; J Ershova; N Ismail; D Burton; H Menzies
Journal:  Int J Tuberc Lung Dis       Date:  2015-06       Impact factor: 2.373

2.  Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis.

Authors:  Anthony J Garcia-Prats; Heather R Draper; Stephanie Thee; Kelly E Dooley; Helen M McIlleron; James A Seddon; Lubbe Wiesner; Sandra Castel; H Simon Schaaf; Anneke C Hesseling
Journal:  Antimicrob Agents Chemother       Date:  2015-07-20       Impact factor: 5.191

Review 3.  The impact of HIV and antiretroviral therapy on TB risk in children: a systematic review and meta-analysis.

Authors:  P J Dodd; A J Prendergast; C Beecroft; B Kampmann; J A Seddon
Journal:  Thorax       Date:  2017-01-23       Impact factor: 9.139

4.  Complementary surveillance strategies are needed to better characterise the epidemiology, care pathways and treatment outcomes of tuberculosis in children.

Authors:  Karen du Preez; H Simon Schaaf; Rory Dunbar; Elisabetta Walters; Alvera Swartz; Regan Solomons; Anneke C Hesseling
Journal:  BMC Public Health       Date:  2018-03-23       Impact factor: 3.295

5.  Pre-treatment loss to follow-up among children with multidrug-resistant tuberculosis in South Africa, 2008-2010.

Authors:  Brittany K Moore; Linda Erasmus; Julia Ershova; Sarah E Smith; Norbert Ndjeka; Laura J Podewils
Journal:  PLoS One       Date:  2020-04-07       Impact factor: 3.240

6.  Bedaquiline for multidrug-resistant TB in paediatric patients.

Authors:  R Moodliar; V Aksenova; M V G Frias; J van de Logt; S Rossenu; E Birmingham; S Zhuo; G Mao; N Lounis; C Kambili; N Bakare
Journal:  Int J Tuberc Lung Dis       Date:  2021-09-01       Impact factor: 2.373

7.  Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.

Authors:  Elizabeth P Harausz; Anthony J Garcia-Prats; Stephanie Law; H Simon Schaaf; Tamara Kredo; James A Seddon; Dick Menzies; Anna Turkova; Jay Achar; Farhana Amanullah; Pennan Barry; Mercedes Becerra; Edward D Chan; Pei Chun Chan; Domnica Ioana Chiotan; Aldo Crossa; Peter C Drobac; Lee Fairlie; Dennis Falzon; Jennifer Flood; Medea Gegia; Robert M Hicks; Petros Isaakidis; S M Kadri; Beate Kampmann; Shabir A Madhi; Else Marais; Andrei Mariandyshev; Ana Méndez-Echevarría; Brittany Kathryn Moore; Parpieva Nargiza; Iveta Ozere; Nesri Padayatchi; Saleem- Ur-Rehman; Natasha Rybak; Begoña Santiago-Garcia; N Sarita Shah; Sangeeta Sharma; Tae Sun Shim; Alena Skrahina; Antoni Soriano-Arandes; Martin van den Boom; Marieke J van der Werf; Tjip S van der Werf; Bhanu Williams; Elena Yablokova; Jae-Joon Yim; Jennifer Furin; Anneke C Hesseling
Journal:  PLoS Med       Date:  2018-07-11       Impact factor: 11.069
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.